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ACR = American College of Rheumatology; AE = adverse event; ATTRACT = Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomi-
tant Therapy; CI = confidence interval; DMARDs = disease-modifying antirheumatic drugs; ERA = Early Rheumatoid Arthritis; ESR = erythrocyte
sedimentation rate; HAQ = Health Assessment Questionnaire; NSAID = non-steroidal anti-inflammatory drug; RA = rheumatoid arthritis; TNF = tumor
necrosis factor.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflamma-
tory disease that affects approximately 1% of the world’s
population. It is characterized by a loss in functional
capacity resulting from decreased structural integrity of
the joints, diminished muscle strength and tone, and a
variety of psychosocial factors. A 10-year outcomes study
of 183 patients with early RA showed that most (94%) are
able to manage daily life activities. On the basis of disabil-
ity scores on the Health Assessment Questionnaire
(HAQ), a self-reported measure of functional impairment,
20% of patients had no disability, 28% were mildly dis-
abled, and 10% were seriously disabled [1].
Treatment strategies have traditionally involved the use of
disease-modifying antirheumatic agents (DMARDs) and,
more recently, the tumor necrosis factor (TNF) antago-
nists. To optimize the functional outcomes of patients with
RA, it is essential to examine the role of these newer
agents in preventing disease progression and, potentially,
in producing a cure. This examination requires several
considerations, including (1) the importance of treating
patients early, (2) the fact that improvements in symptom
control do not necessarily signal reduced disease pro-
gression and disability, (3) the emergence of structure-
related parameters as a primary means of assessing
response to therapy, (4) therapeutic alternatives for
patients who do not respond satisfactorily to one anti-TNF
agent, and (5) discontinuation rates and whether they
influence therapy, given the desire for durable clinical
responses.
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Abstract
Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly
improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in
which structural joint damage can continue to develop even in the face of symptomatic relief. Before the
introduction of biologic agents, the management of RA involved the use of disease-modifying
antirheumatic drugs (DMARDs) early in the course of disease. This focus on early treatment, combined
with the availability of the anti-TNF agents, has contributed to a shift in treatment paradigms favoring the
early and timely use of DMARDs with biologic therapies. Improvement in symptom control does not
always equate to a reduction in disease progression or disability. With the emergence of structure-
related outcome measures as the primary means for assessing the effectiveness of antirheumatic
agents, the regular use of X-rays is recommended for the continued monitoring and evaluation of
patients. In addition to the control of symptoms and improvement in physical function, a reduction in
erosions and joint-space narrowing should be considered among the goals of therapy, leading to a
better quality of life. Adherence to therapy is an important element in optimizing outcomes. Durability of
therapy with anti-TNF agents as reported from clinical trials can also be achieved in the clinical setting.
Concomitant methotrexate therapy might be important in maintaining TNF antagonist therapy in the long
term. Overall, the TNF antagonists have led to improvements in clinical and radiographic outcomes in
patients with RA, especially those who have failed to show a complete response to methotrexate.
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The importance of treating patients early
One nonrandomized, comparative study of pre-biologic
therapies (namely standard DMARDs) compared the
effects of delayed and early treatment on disease
outcome in 206 patients with probable or definite recent-
onset RA as defined by the 1958 and 1987 American
College of Rheumatology (ACR) criteria, respectively
[2,3]. The delayed treatment group (n=109) received
nonsteroidal anti-inflammatory drugs (NSAIDs) followed
by the administration of standard DMARDs – chloroquine
or salazopyrine – at a mean of 123 days after diagnosis.
The early treatment group (n=97) received NSAIDs with
standard DMARDs at a mean of 15 days after the diagno-
sis (Fig.1) [2]. Results at 2 years indicated less radi-
ographically evident joint destruction in the
early-treatment group than in the delayed-treatment group
(median Sharp scores: 3.5 versus 10; P<0.05). Thus,
even with non-biologic therapies, a delay in therapy
resulted in poorer outcomes.
The advantages of the early initiation of therapy com-
bined with the introduction of newer antirheumatic
agents (such as the TNF biologic response modifiers)
have shifted treatment models toward the earlier and
more timely use of DMARDs [4] and biologic therapy
[5,6]. A panel of rheumatic disease experts has issued a
consensus report addressing the role of TNF antagonists
in patients with RA; the panel stated that TNF antago-
nists may become first-line agents in the treatment of RA
and should not be reserved for patients with advanced
disease [6].
Improvements in symptom control do not
necessarily signal reduced disease
progression and disability
A study by Wolfe investigated the relationship between
HAQ disability scores and the clinical course of RA in
1843 patients [7]. Analysis of 1-year, 2-year, and 3-year
data from this study indicates that HAQ disability scores
might increase gradually with significant increases in
structural damage, as assessed by Larsen index scores
(data on file, Centocor, Inc., Malvern, PA, USA) (Table 1).
There might also be a discrepancy between disease
course and the presence of clinical indicators of disease
such as pain, swollen joint count, and tender joint count.
Wolfe and Sharp compared clinical disease assessment
and radiographic progression in 256 patients with RA who
were seen within 2 years of disease onset and were fol-
lowed for up to 19 years [8]. On the basis of Sharp
scores, joint-space narrowing, and erosion scores, it was
concluded that RA progresses at a constant, linear rate
that is neither greater in early RA nor reduced later in the
course of disease (Fig.2), and that other factors (such as
mean erythrocyte sedimentation rate [ESR], mean grip
strength, rheumatoid factor positivity, and swollen joint
count) serve as independent predictors of radiographically
evident joint destruction [8].
The emergence of structure-related
parameters as a primary means of assessing
response to therapy
The 2002 ACR Guidelines for the management of
rheumatoid arthritis state that the ultimate goals of RA
management are the prevention or control of joint damage,
the prevention of loss of function, and the amelioration of
pain [5]. Kirwan described a potential pathogenic pathway
for RA that supports these principles, showing a possible
correlation between clinical symptoms and X-ray changes
in RA (Fig.3) [9].
As assessment of structural damage in RA is emerging as
an important method of evaluating disease outcomes, radi-
ographs (that is, X-rays), have become essential tools not
just for the diagnosis of RA but for continued monitoring.
Radiographic findings can be reported with the Sharp
score or the Larsen index. The total Sharp score is derived
from the combination of erosion and joint-space narrowing
Figure 1
Study of delayed and early treatment on disease outcome in patients
with recent-onset rheumatoid arthritis (RA). *P<0.05 compared with
the delayed-treatment group. Adapted, with permission, from Excerpta
Medica [2].
0
2
4
6
8
10
12
14
0 6 12 18 24
* *
Months
Delayed
treatment
Early treatment
S
h
a
r
p
 
s
c
o
r
e
Table 1
Improved symptom control with disease progression
Score
Parameter Year 1 Year 2 Year 3 Outcome
Mean SJC 5.2 3.5 2.4 Reduced symptoms
Mean TJC 13.7 9.0 6.5 Reduced symptoms
Mean pain 22.4 13.4 11.1 Reduced symptoms
Mean Larsen 5.6 12.3 16.9 Increased structural
index damage
SJC, swollen joint count (maximum score 44); TJC, tender joint count
(maximum score 53). Data on file, Centocor, Inc., Malvern, PA, USA.S26
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scores. Joint-space narrowing is not a major contributor to
the overall Larsen index score [10].
Both Sharp and Larsen scores have been used to report
outcome assessment data in clinical trials of TNF antago-
nists. The Anti-Tumor Necrosis Factor Trial in Rheumatoid
Arthritis With Concomitant Therapy (ATTRACT) was a
2-year, double-blind, placebo-controlled study that
showed that the TNF antagonist infliximab, in combination
with methotrexate, was superior to methotrexate alone in
improving the radiographic outcomes of patients with RA
[11–13]. At the 52-week endpoint, the infliximab-treated
patients showed improvements in erosion, joint-space nar-
rowing, and Sharp scores (Fig.4) [12].
The Early Rheumatoid Arthritis (ERA) trial compared the
efficacy of etanercept and methotrexate in 632 patients
with early RA [14,15]. This trial consisted of a 1-year
blinded phase [14] and a 1-year open-label extension
phase [15]. Results at 2 years showed a significantly
decreased incidence of structural joint disease in the
etanercept-treated patients, as determined by changes
in Sharp score (P=0.001) and erosion score
(P=0.001); however, there was no statistically signifi-
cant difference in joint-space narrowing scores (Fig.5)
[15]. These two trials show how TNF antagonists have
raised the standard of treating patients with RA on the
basis of their shown ability to produce significant
improvements in clinical parameters (such as ACR
response) and to retard the radiographically assessed
progression of joint damage.
Although radiographic evidence of disease progression is
frequently assessed by Sharp scores, clinical data are
usually assessed by ACR criteria, such as the ACR20.
Achievement of an ACR20 response indicates a greater
than 20% improvement in tender and swollen joint counts
and at least three of the following disease activity vari-
ables: the patient’s assessment of pain, the patient’s
global assessment of disease activity, the physician’s
global assessment of disease activity, the patient’s
assessment of physical function, and the ESR or the
C-reactive protein level [5,16]. However, failure to achieve
an ACR20 response should not necessarily be interpreted
as a failure of therapy. Preliminary subgroup analysis data
from the ATTRACT study indicate that in patients who
failed to achieve an ACR20 response (that is, non-respon-
ders), those treated with infliximab and methotrexate
showed a greater improvement in ACR20 response than
the patients treated with methotrexate alone (Fig.6) (data
on file, Centocor, Inc.). Thus, the regular use of
Figure 2
Change in Sharp scores, joint-space narrowing (JSN), and joint
erosion (JE) scores showing that rheumatoid arthritis progresses at a
constant, linear rate. Adapted, with permission, from John Wiley &
Sons, Inc. [8].
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Figure 3
Potential pathogenic pathway for rheumatoid arthritis, supporting a
relationship between structural damage and clinical symptoms.
Adapted, with permission, from Excerpta Medica [9].
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Figure 4
Data from the ATTRACT (Anti-Tumor Necrosis Factor Trial in
Rheumatoid Arthritis With Concomitant Therapy) study showing the
superiority of infliximab plus methotrexate (MTX) over methotrexate
alone, as determined by the median change in the modified Sharp
score. Data from [12].
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radiographic imaging, including X-rays, can be considered
an important component of the overall assessment and
evaluation of patients with RA.
Therapeutic alternatives for patients who do
not respond satisfactorily to one anti-TNF
agent
The failure of a patient to respond to a single TNF antago-
nist should not be taken to mean that the patient is refrac-
tory to all TNF antagonists. Studies have shown success
with infliximab in patients who have failed to respond to
etanercept therapy, and vice versa. In one study, investiga-
tors in community rheumatology practices documented
the efficacy and safety of infliximab in patients with an
inadequate response to etanercept [17]. After four infu-
sions of infliximab, patients experienced reductions in
mean tender joint counts (57%), mean swollen joint
counts (66%), ESR (20%), and mean daily prednisone
requirement (38%) (Table 2) [17]. Although this study
lacks the structure of a randomized controlled clinical trial,
it provides preliminary data that TNF antagonist therapy
should not be abandoned in the face of an apparent initial
unsatisfactory response.
Do discontinuation rates influence therapy?
Discontinuation rates of a pharmacologic agent, including
antirheumatic agents, can influence therapy. Discontinua-
tion rates can serve as a reasonable guide to the efficacy
or safety of an agent. Before definitive conclusions can be
made, other variables should be considered, for example
the phase of therapy (such as acute, continuation, mainte-
nance), reasons for the discontinuation (such as lack of
efficacy, toxicity, adverse events [AEs]), associated symp-
toms or intercurrent illness, and drug profile (including
previous medications and concomitant therapy). Discontin-
uation rates can also serve as a reflection of the chronic,
aggressive course of the disease, which can require more
than one therapy or can sometimes involve the switching of
agents to achieve satisfactory clinical outcomes.
For a better understanding of how discontinuation rates
affect therapy in the era of anti-TNF agents, a review of the
discontinuation rates with DMARDs based on three large
studies is presented [18–20]. According to a Markov
model based on the Arthritis, Rheumatism, and Aging
Available online http://arthritis-research.com/content/6/S2/S24
Figure 5
Data from the ERA (Early Rheumatoid Arthritis) trial showing the
superiority of etanercept over methotrexate, as determined by
improvements in erosion and Sharp scores, but not joint-space
narrowing score at 2 years. Adapted, with permission, from John Wiley
& Sons, Inc. [15].
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Table 2
Clinical changes after a switch from etanercept to infliximab
Post-infliximab
Pre-infliximab (4 doses;
Parameter (baseline) week 14) Outcome
Mean tender joints (n) 17.1 7.3 57% reduction
Mean swollen joints (n) 11.2 3.8 66% reduction
ESR (mm/h) 33 26.5 20% reduction
Mean prednisone dosage 9.2 5.7 38% reduction
(mg/day)
ESR, erythrocyte sedimentation rate. Data from [17].
Figure 6
Preliminary radiographic data from the ATTRACT (Anti-Tumor Necrosis
Factor Trial in Rheumatoid Arthritis With Concomitant Therapy) study,
indicating the superiority of infliximab plus methotrexate over
methotrexate alone in patients who did and did not achieve an ACR20
(that is, ACR20 responders and non-responders). ACR20 is a more
than 20% improvement in tender and swollen joint counts and at least
three of the following disease activity variables: the patient’s
assessment of pain, the patient’s global assessment of disease activity,
the physician’s global assessment of disease activity, the patient’s
assessment of physical function, and the erythrocyte sedimentation
rate or C-reactive protein level. *P<0.05 versus placebo. Data on file,
Centocor, Inc., Malvern, PA, USA.
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Medical Information System (ARAMIS) postmarketing
surveillance cohort (n=4285 consecutively enrolled
patients with RA who were followed up for 17,085
patient-years), 46–60% of patients initially receiving
methotrexate alone would still be on methotrexate alone or
with a DMARD after 5 years [20]. When patterns of drug
use in patients with RA in a community setting were evalu-
ated, drug discontinuation and medication switching were
observed to be common [19]. Almost 20% (1300 of
6944) of patients who took at least one antirheumatic
drug during the study year used a DMARD, with
methotrexate being the most frequently used. Of the
DMARD users, 23% discontinued the drug during the
study year, 19% were taking other concurrent DMARDs,
and 16% added another DMARD. DMARDs were often
used with other (that is, non-DMARD) agents, because
63% of DMARD users were also taking an NSAID and
61% were taking a corticosteroid [19]. Aletaha and
Smolen [18] evaluated the treatment patterns with tradi-
tional DMARDs and their changes during the two decades
before the introduction of newer antirheumatic agents. The
study involved 593 patients with RA who were followed
from their first presentation in the clinic throughout the
course of their disease, of whom 222 patients received
their first DMARD during the study [18]. Before 1985
most (65–90%) of initial DMARDs were gold compounds,
whereas after 1985 methotrexate was the initial DMARD
in 29% of new patients. Patients with high disease activity
were more likely to be receiving methotrexate than other
DMARDs, and first DMARDs in new patients were used
for longer than subsequent DMARDs, because they were
more effective [18]. On the basis of an analysis of 122
controlled trials and observational studies involving
16,071 patients with RA, Hawley and Wolfe [21] con-
cluded that good retention rates in studies lasting
3–12 months were not representative of long-term results,
although the retention rates observed in controlled and
observational studies were similar during the first treat-
ment year.
Discontinuation rates for anti-TNF agents as observed in
two long-term, randomized RA trials, one involving inflix-
imab (ATTRACT) and the other etanercept (ERA), are
listed in Table 3 [12,14]. These trials differed in terms of
study size (428 versus 632 patients), stage of RA (later-
stage [active] versus early), and regimens (anti-TNF
therapy plus a DMARD compared with placebo plus a
DMARD [ATTRACT], versus anti-TNF monotherapy
compared with a DMARD [ERA]). In the ATTRACT
study, in which patients were randomized to receive 3
or 10mg of infliximab every 4 or 8 weeks, or placebo,
with methotrexate given to all groups, 54-week data
showed that discontinuation rates due to AEs were
about 8% (26 of 340) in infliximab-treated patients com-
pared with about 16% (7 of 44) of patients in the
placebo-plus-methotrexate group [12]. The discontinua-
tion rates due to lack of efficacy were about 12% (40 of
340) in the infliximab-treated patients compared with
about 73% (32 of 44) in the placebo-plus-methotrexate
group. In the ERA trial, in which patients were random-
ized to receive 10 or 25mg of etanercept twice weekly,
or methotrexate weekly, discontinuation rates due to
AEs or elevated aminotransferase levels were 6% for
the group receiving 10mg of etanercept, 5% for the
group receiving 25mg of etanercept (P<0.001 versus
methotrexate), and 11% for the methotrexate group
[14]. Lack of efficacy was the reason for discontinuation
in 7% and 5% of patients in the groups receiving 10
and 25mg of etanercept, respectively, versus 4% in the
methotrexate group [14].
The chronic course of RA merits long-term maintenance
therapy. Efforts to lower discontinuation rates have
included the administration of methotrexate together with
anti-TNF agents. Support for enhanced therapeutic effi-
cacy with this approach has been documented [22,23].
Maini and colleagues conducted a 26-week, double-blind,
placebo-controlled trial in 101 patients with active RA
exhibiting an incomplete response to methotrexate (about
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Table 3
Discontinuation rates at 1 year for anti-TNF agents in randomized clinical trials
No. of
Trial patients Patient characteristics Regimens Discontinuation rates (%)
ATTRACT [12] 428 Active RA despite methotrexate therapy;  Infliximaba 21
mean duration 9–12 years 3 mg q 4 weeks
3 mg q 8 weeks
10 mg q 4 weeks
10 mg q 8 weeks
Placeboa (weekly) 50
ERA [14] 632 Early RA; Etanercept
mean duration <1 year (i.e. 11–12 months) 25 mg twice weekly 15
Methotrexate (mean, 19 mg) weekly 21
aAll groups also received methotrexate, mean 16–17 mg/week.
ATTRACT, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy; ERA, Early Rheumatoid Arthritis.S29
9–15 mg per week for the last 3 months before the study)
[22]. Patients received either infliximab 1, 3, or 10mg/kg
intravenously with or without methotrexate 7.5mg per
week, or placebo plus methotrexate 7.5mg per week intra-
venously at weeks 0, 2, 6, 10, and 14; follow-up continued
until week 26 [22]. Results showed that when infliximab
(at all dose regimens in the study) was administered
together with infliximab and weekly methotrexate, 60–80%
of patients attained a Paulus 20% response for up to
14 weeks, and 50–60% of patients sustained a response
after the cessation of treatment until the end of the study
[22]. In the ATTRACT study, the combination of infliximab
and methotrexate over 30, 54, and 102 weeks provided
significant, clinically relevant improvement in a majority of
patients with RA who had an incomplete response to
methotrexate alone; however, discontinuation rate data at
102 weeks have yet to be made available [11–13]. As
more data from long-term trials that involve these agents
accumulate, focusing on discontinuation rates and corre-
lating safety and efficacy parameters, the role of concomi-
tant methotrexate in the long-term maintenance of
anti-TNF therapy will be clarified further.
Aside from clinical trial data, clinical practice data report
the discontinuation rates of anti-TNF agents. A 2-year
Swedish study conducted in seven clinical centers evalu-
ated the anti-TNF agents infliximab (n=135) and etaner-
cept (n=166]) and a newer-generation DMARD,
leflunomide (n=103), for efficacy (based on ACR
response criteria) and tolerability (based on survival and
AEs) in patients with RA [24]. Initial doses of the agents in
this study were 3mg/kg intravenously at weeks 0, 2, 6,
and 12 and every 8 weeks thereafter for infliximab, and
25mg subcutaneously twice weekly for etanercept; appro-
priate dose adjustments and switching to another of the
three agents were allowed after withdrawal from one treat-
ment [24]. On the basis of ACR20 and ACR50
responses, the TNF antagonists performed significantly
better than the newer DMARD, and no significant differ-
ences were noted between the efficacy of infliximab and
etanercept at 0.5, 1.5, 9, and 12 months [24]. At
3 months, ACR20 and ACR50 responses were noted in a
greater percentage of patients who received infliximab
than leflunomide (P<0.01 and P<0.05, respectively),
whereas ACR20 and ACR50 responses were noted in a
greater percentage of etanercept-treated and leflunomide-
treated patients at 3 months (P<0.001) and 6 months
(P<0.05) [24]. Survival data showed that 75%, 79%, and
22% of patients continued to receive infliximab, etaner-
cept, and leflunomide, respectively, after 20 months (for
24-month discontinuation rates of 25%, 21%, and 78%,
respectively) [24]. In the infliximab-treated and etanercept-
treated patients in this study, AEs were the primary cause
of drug discontinuation. There were 2.8 life-threatening
AEs per 100 treatment-years (namely anaphylactoid reac-
tion, mesothelioma, and severe pharyngitis) and 10.0
serious AEs per 100 treatment-years (namely allergic
reactions, bacterial infections, Hodgkin’s/non-Hodgkin’s
lymphoma, thrombocytopenia, lupus-like reaction, discoid
lupus) with infliximab. Etanercept-treated patients experi-
enced 1.3 fatal AEs per 100 treatment-years (namely gas-
troenteritis, immunocytoma of the breast, and myocardial
infarction) and 7.0 serious AEs per 100 treatment-years
(namely myocardial infarction, bacterial infections, uterine
cervical carcinoma, leukemia, malaise, leucopenia, Bell’s
paralysis, cutaneous vasculitis, discoid lupus) [24].
An electronic medical record system was used to review
all patients seen in a university rheumatology clinic (the
Arizona Arthritis Center at the University of Arizona) who
had been treated with infliximab (n=118) or etanercept
(n=90) between February 1998 and May 2002 [25].
Data were collected on diagnosis, disease duration, dates
of therapy, reasons for treatment discontinuation, and AEs
and serious AEs. Most (82%) of the 208 patients in this
study had a diagnosis of RA [25]. Kaplan–Meier analysis
for the discontinuation of any anti-TNF therapy showed a
mean medication duration of 768 days (95% confidence
interval [CI] 693–843 days) with a maximum follow-up
time of 1260 days [25].
For infliximab, the mean time to discontinuation was
931 days (95% CI 844–1018 days), with 32 (27%) of
118 patients discontinuing infliximab. After 15 months
there was a 0% rate of discontinuation with infliximab [25].
For etanercept, the mean time to discontinuation was
595 days (95% CI 491–700 days), with 58 (64%) of
90 patients discontinuing etanercept [25]. The log-rank
test coefficient for the difference between survival curves
for the two groups was 20.03 (P<0.01) and the
Gehan–Breslow coefficient was 16.01 (P<0.001) [25].
The investigators documented a low probability of discon-
tinuations of infliximab after 1 year of treatment and con-
cluded that, on the basis of the results of the survival
analysis of the data from their practice, patients receiving
infliximab remain on therapy significantly longer than those
on etanercept [25].
Conclusion
Clinical trials and community findings support the efficacy
and safety of the current TNF antagonists. To optimize
comprehensive therapeutic outcomes in clinical practice,
DMARDs or anti-TNF agents, or both, should be instituted
early, and patient status and response to therapy should
be monitored on a regular basis by using X-rays and radi-
ographic scores. Structure-related parameters are emerg-
ing as a most important measure of outcome by which the
efficacy of antirheumatic therapies are evaluated. In addi-
tion to a reduction of symptoms and improvement in physi-
cal function, optimal reductions in erosions and
joint-space narrowing should be part of the goals of
therapy. Patients who show an unsatisfactory response to
Available online http://arthritis-research.com/content/6/S2/S24S30
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one anti-TNF agent should be started on another. Adher-
ence to therapy is an important element in optimizing out-
comes, and durability of therapy can also be achieved in
the clinical setting. Finally, the concomitant administration
of methotrexate might be important in the maintenance of
TNF antagonist therapy in the long term. Overall, the TNF
antagonists have provided significant improvements in
clinical and radiographic outcomes for patients with RA,
especially those who have had an incomplete response to
methotrexate therapy.
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